Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | F13A1 | P00488 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | TGM1 | P22735 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1229961 | 0.82 | USP2 (0.69) | MAPTALDH1A1PKMUSP2LMNA | |
| SCHEMBL421626 | 0.82 | USP2 (0.63) | MAPTALDH1A1PKMUSP2LMNA | |
| SCHEMBL5657050 | 0.81 | LMNA (0.61) | MAPTALDH1A1PKMUSP2LMNA | |
| Hydrochloric Acid SCHEMBL8130433 | 0.81 | MAPT (0.64) | MAPTALDH1A1PKMLMNAHTR6 | |
| SCHEMBL17246 | 0.81 | MAPT (0.68) | MAPTALDH1A1PKMLMNAHTR6 | |
| SCHEMBL893688 | 0.81 | MAPT (0.68) | MAPTALDH1A1PKMLMNAHTR6 | |
| SCHEMBL76639 | 0.81 | USP2 (0.73) | MAPTALDH1A1USP2LMNA | |
| SCHEMBL2122633 | 0.81 | USP2 (0.73) | MAPTALDH1A1USP2LMNA | |
| Hydrochloric Acid SCHEMBL16186 | 0.79 | MAPT (0.66) | MAPTALDH1A1PKMLMNAHTR6 | |
| SCHEMBL15284182 | 0.79 | MAPT (0.66) | MAPTALDH1A1PKMLMNAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596706-B1 | For the treatment of circulatory diseases cerebral diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | claimed |
| EP-1029872-A1 | PIPERAZINE-CYCLODEXTRIN COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-23 | — | — | EP | claimed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | claimed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | claimed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | claimed |
| WO-2023160638-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-08-31 | — | — | WO | disclosed |
| WO-2020207570-A1 | PHENAZINES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS 2 (DDR2) | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-10-15 | — | — | WO | disclosed |
| WO-2020207611-A1 | PHENAZINES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS 2 (DDR2) | ROTTAPHARM BIOTECH S.R.L. (IT) | 2020-10-15 | — | — | WO | disclosed |
| WO-2008053199-A1 | COMBINATION THERAPY FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
| WO-2004043924-A1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | WO | disclosed |
| US-6596706-B1 | For the treatment of circulatory diseases cerebral diseases | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| CN-1278269-A | Piperazine-cyclodextrin complexes | DAIICHI PHARMACEUTIAL CO LTD (JP) | 2000-12-27 | — | — | CN | disclosed |
| EP-1029872-A1 | PIPERAZINE-CYCLODEXTRIN COMPLEXES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | MAPT 4830/4885ALDH1A1 2221/4885PKM 3815/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | MAPT 3282/4885ALDH1A1 3322/4885PKM 1319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.